Parameter | Recurrence group (n = 29) | Non-recurrence group (n = 44) | P value |
---|---|---|---|
Recipient age | 48(21–67) | 49.5(33–62) | 0.811 |
≥ 50 | 13(44.8%) | 22(50.0%) | |
<50 | 16(55.2%) | 22(50.0%) | |
Recipient gender | 1.000 | ||
Male | 25(86.2%) | 39(88.6%) | |
female | 4(13.8%) | 5(11.4%) | |
Hepatitis B | 0.207 | ||
Yes | 25(86.2)%) | 42(95.5%) | |
No | 4(13.8%) | 2(4.5%) | |
Cirrhosis | 0.154 | ||
Yes | 20(69.0%) | 37(84.1%) | |
No | 9(31.0%) | 7(15.9%) | |
Milan criteria | 0.000 | ||
In | 2(6.9%) | 29(65.9%) | |
Out | 27(93.1%) | 15(34.1%) | |
TNM stage | 0.000 | ||
1–2 | 12(41.4%) | 38(86.4%) | |
3–4 | 17(58.6%) | 6(13.6%) | |
Tumor size (cm) | 0.000 | ||
> 5 | 26(89.7%) | 18(40.9%) | |
≤ 5 | 3(10.3%) | 26(59.1%) | |
Multinodular type | 0.219 | ||
YES | 15(51.7%) | 30(68.2%) | |
NO | 14(48.3%) | 14(31.8%) | |
Pre-OLT serum AFP level | 0.165 | ||
≤ 400 (ng/ml) | 19(65.5%) | 36(81.8%) | |
> 400 (ng/ml) | 10(34.5%) | 8(18.2%) | |
Microvascular invasion | 0.000 | ||
Yes | 14(48.3%) | 2(4.5%) | |
No | 15(51.7%) | 42(95.5%) | |
Macrovascular invasion | 0.425 | ||
YES | 4(57.1%) | 3(42.9%) | |
NO | 25(37.9%) | 41(62.1%) |